Olopatadine/mometasone
Combination of
OlopatadineSelective histamine H1-receptor antagonist
MometasoneCorticosteroid
Clinical data
Trade namesRyaltris
Other namesGSP 301
License data
Pregnancy
category
Routes of
administration		Nasal spray
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older.[1][2][3] It contains olopatadine hydrochloride and mometasone furoate monohydrate.[1][2] It is sprayed into the nose.[1][2]

Common side effects include an unpleasant taste (dysgeusia).[1]

It was approved for medical use in Australia in December 2019,[1][4] and in the United States in January 2022.[2]

References

  1. ^ a b c d e f g "Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) Nasal Spray". Retrieved 25 July 2020.
  2. ^ a b c d e "Ryaltris- olopatadine hydrochloride and mometasone furoate spray, metered". DailyMed. 9 January 2022. Retrieved 20 June 2022.
  3. ^ Chen R, Zheng D, Zhang Y, Sima G (September 2021). "Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis". European Archives of Oto-rhino-laryngology. 279 (4): 1691–1699. doi:10.1007/s00405-021-07085-w. PMID 34591150. S2CID 238223252.
  4. ^ "Ryaltris nasal spray approved in Australia". OINDPnews. 20 December 2019. Retrieved 25 July 2020.

External links


Decongestants and other nasal preparations (R01)
More
Categories